Recruiting PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT06756152

Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis

Prospective Pilot Study of the Clinical Efficacy and Safety of the Method for Preventing a Graft-versus-host Disease Through the Agency of Using the Combination of Post-transplantation Cyclophosphamide with Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis After Hematopoietic Stem Cell Transplantation from an Unrelated or Haploidentic Donor

Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Conditions Acute Lymphoblastic Leukemia Bilinear Leukemia Biphenotypic Acute Leukemia Malignant Lymphoma, Non-Hodgkin Myeloblastic Leukemia Myelodysplastic Syndrome

Interventions Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150

Updated 2 times since 2025 Last updated: Dec 24, 2024 Started: Jul 10, 2024 Primary completion: Jul 10, 2026 Completion: Oct 10, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06756152, this PHASE2/PHASE3 trial focuses on Acute Lymphoblastic Leukemia and Bilinear Leukemia and remains actively recruiting participants. Sponsored by Federal Research Institute of Pediatric Hematology, Oncology and Immunology, it has been updated 2 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE2/PHASE3
Feb 2025 — Sep 2025 [monthly]

Recruiting PHASE2/PHASE3

First recorded

Jul 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Data source: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Moscow, Russia